5,7-dihydroxy-11-ketotetranorprostanoic acid

The metabolism of F series prostaglandins (PGs), including PGF1α and PGF2α, commonly begins with the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω carbon produces the abundant urinary metabolites, including tetranor-PGFM. 13,14-dihydro-15-keto tetranor PGF1α is a potential metabolite of either PGF1α or PGF2α and likely precursor to tetranor-PGFM.